Clinical observations indicate that the antibody response to herpes simplex virus (HSV) in patients undergoing acyclovir treatment is reduced and, although the exact mechanism is not clear, some authors interpret it as immunosuppression. In order to clarify the mechanism, we cutaneously infected mice with HSV-1 and treated the resulting skin lesions with acyclovir. The immune response to infection and treatment in these mice was then analysed. Acyclovir treatment was given orally (20 mg/kg, three times daily), starting on day 0 (D0), 2 (D2) or 4 (D4) after infection and continuing until day 10. The serum antibody titre and the severity of skin lesions were significantly higher in the shortest treatment group (D4) than in the longer treatment groups (D0 and D2). In contrast, a skin test analysing delayed-type hypersensitivity (DTH) to HSV antigen showed that the D0 and D2 groups exhibited stronger DTH than the D4 group. Acyclovir treatment failed to cause a dissociation between DTH and antibody production in mice immunized with inactivated HSV antigen. However, acyclovir treatment in infected mice suppressed the development of skin lesions and resulted in a dissociation between DTH response and antibody production, indicating a typical immune deviation. This was supported by a change in the ratio of the isotype antibody IgG2a to IgG1. The treatment of skin lesions with acyclovir reduced the level of antibody response, as observed clinically. This indicates that the reduced antibody response in patients treated with acyclovir may be, at least in part, due to immune deviation and not immunosuppression.
Herpes simplex virus (HSV) causes diseases that are troublesome although rarely lethal. Acyclovir has been successfully used as a treatment for HSV infection for a number of years. It significantly reduces the severity of skin lesions in the clinical course of primary HSV infection, as well as modulating the immune response. However, the correlation between the severity of skin lesions and the level of the cellmediated and humoral immune responses is poorly documented. Some researchers have demonstrated that acyclovir can reduce the rise in antibody production on infection when compared with placebo treatment (Ashley & Corey, 1984; Bernstein et al., 1984; Erlich et al., 1988; Gold et al., 1988; Ragab et al., 1989; Kawana et al., 1995; Hu et al., 1997) . Other researchers have found that both the lymphocyte proliferative response and antibody production were lower in acyclovir-treated patients compared to placebotreated patients (Lafferty et al., 1984; Mitchell et al., 1986) . Some authors (Bernstein et al., 1984; Erlish et al., 1988; Kawana et al., 1995) have interpreted these observations as an immunosuppressive effect of acyclovir treatment.
In order to understand the influence of acyclovir treatment on both the cellular and humoral immune responses, we evaluated the effects of acyclovir on the delayed-type hypersensitivity (DTH) response and the production of IgG antibody and IgG isotypes against HSV antigen in a mouse cutaneous infection model. The results showed that an earlier start and longer period of acyclovir treatment resulted in reduced severity of skin lesions, as well as an enhanced DTH reaction and reduced antibody production. A later start and shorter period of treatment resulted in more severe skin lesions and led to a weaker DTH reaction, but a higher level of antibody production. Thus, acyclovir 
Materials and Methods

Virus and cells
The HSV-1 7401H strain was propagated in human embryonic lung (HEL) cells. HEL cells were infected with virus or mock infected with medium for 1 h at room temperature and incubated in Eagle's MEM supplemented with 2% foetal bovine serum for about 48 h at 37 o C in a 5% CO 2 incubator (Kurokawa et al., 1993; Nagasaka et al., 1995; Li et al., 1997) . When CPE was observed in about 50% of the cultured cells, the culture medium was replaced with serumfree medium and further incubated until harvest. The infected and mock-infected cultures were frozen and thawed three times and centrifuged at 3000 r.p.m. for 15 min. After determination of the virus titre, each supernatant was stored as virus or mock virus stock at -80 o C until use.
Cutaneous infection and treatment with acyclovir
The procedures used for HSV infection in the three separate experiments of this study have been reported previously (Kurokawa et al., 1993; Nagasaka et al., 1995; Li et al., 1997) . Briefly, specific-pathogen-free 7-week-old BALB/c mice were purchased from Kiwa Laboratory Animal Research Institute (Wakayama, Japan). The right midflank of each mouse was clipped with hair clippers and depilated with a chemical depilatory (Shiseido, Tokyo, Japan). The mice were randomly divided into five groups with 10 mice in each group: mock-infected (UC) without any treatment; infected control (IC) (20 mice were used in this group because it was anticipated that there would be severe mortality), treated with water; infected and treated with acyclovir from day 0 (D0) (day of infection) to day 10 post-infection (p.i.); infected and treated with acyclovir from day 2 (D2) to day 10 p.i.; infected and acyclovir-treated from day 4 (D4) to day 10 p.i.
The depilated skin of all mice was scratched with a bundle of 27-gauge needles (Simmons et al., 1984; Kurokawa et al., 1993; Nagasaka et al., 1995; Li et al., 1997) , giving a total scarified area of approximately 1.0 cm 2 . This area was infected immediately by spreading a 10 µl drop of mock virus stock or 7401H virus stock containing 2-6×10 5 p.f.u., resulting in superficial infection of the skin. Acyclovir was obtained from 200 mg Zovirax tablets (Nippon Wellcome). The tablets were ground to powder and suspended in water (Otsuka Seiyaku, Tokyo, Japan). Acyclovir (20 mg/kg/dose) or water was orally administered to infected mice, three times daily until day 10 p.i. The skin lesions of all mice were monitored, beginning at day 3 after infection, and scored as described previously Nagasaka et al., 1995; Li et al., 1997) . Briefly, a score of 0 means no lesion occurred; 2, vesicles were observed in a local region; 4, erosion occurred in a local region; 6, a mild zosteriform lesion occurred; 8, moderate and severe zosteriform lesions with ulceration occurred; and 10 resulted in death. Observation was performed 3 times each day at the same time as drug administration and continued until day 14, when mice recovered systemically from illness and skin lesions were reduced to a score of 0.
HSV infection was performed in the infection room of the Laboratory Animal Center (Toyama Medical and Pharmaceutical University). Procedures involving animals and their care conformed to institutional guidelines that are in compliance with international law and policy (Guide for the Care and Use of Laboratory Animals; NIH publication, 1985).
Analysis of DTH
On day 21 p.i., virus stock containing the same titre as used in the cutaneous infection experiment was UV-inactivated and antigens were injected in 10 µl volumes into the right footpads of the mice under ether anaesthesia. The footpad thickness was measured with a screwgauge meter at 24 h, 36 h and 48 h after injection, as described previously Li et al., 1997) .
Determination of IgG and IgG isotype antibody production by ELISA
Individual convalescent serum was collected by retroorbital bleeding under ether anaesthesia on the day after DTH measurement. ELISA plates were coated with HSV-1 antigen or mock antigen overnight at 4 o C. The plates were washed with PBS and blocked with 3% skimmed milk in PBS. The optimum dilution of the first (mouse serum) and second antibodies (horseradish peroxidase-conjugated anti-mouse IgG; Jackson ImmunoResearch Laboratories, Denka Seiken, Niigata Japan); anti-mouse IgG1 and IgG2a (PharMinogen, Zymed Laboratory, San Francisco, Calif., USA); and IgG2b antibodies (Zymed Laboratories, PharMinogen, San Diego, Calif., USA) was determined by box titration. The reaction was visualized by HAT-EIA ( Jackson Immunoresearch, West Grove, Pa, USA). Briefly, antigen concentration was constant at about 5×10 5 p.f.u./well prior to inactivation. Mouse serum was serially diluted from 200-to 102400-fold and anti-mouse IgG or IgG isotypes were serially diluted from 1500-to 48000-fold. A cut-off absorbance (A) value was determined using serum from 10 uninfected control mice. Finally, the optimum dilution of the first and second antibodies was decided from box titration. The combinations of antibody dilutions used were as follows: the mouse serum and anti-mouse IgG antibody were diluted 800-and 12000-fold, respectively, for IgG antibody determination. The mouse serum and antimouse IgG isotype antibodies (IgG1, IgG2a and IgG2b) were diluted 400-and 6000-fold, respectively, for IgG isotype antibody determination. The antibody level was expressed as absorbance at 490 nm.
Determination of the immune responses in mice immunized with inactivated HSV antigen
In order to characterize the effect of acyclovir on immune response, mice were immunized with heat-inactivated HSV antigens. Mice were immunized intradermally in the footpad with antigen. They were then subjected to the same protocol of acyclovir administration, DTH challenge and antibody determination as used in the case of cutaneous infection.
Statistical analysis
Statistical analysis of the difference in the mean values among all groups was performed using Student's t-test.
Results
Effects of acyclovir on the development of skin lesions in mice infected cutaneously with HSV-1 HSV-1 7401H virus-infected mice were treated with acyclovir or water from day 0, day 2 or day 4, three times daily at 20 mg/kg/dose until day 10 p.i. The development of skin lesions was monitored by scoring and is shown in Figure 1 . The UC group did not show any skin lesions. All 20 mice of the IC group showed severe skin lesions, with most dying on day 7. Only one mouse recovered from infection and was used for further examinations. The survival rate was 1/20 in the first and 2/20 in the second experiment (Table 1) . The results from the IC group were obtained from the single mouse that survived and therefore the data were not evaluated. The D0 group showed the mildest skin lesions during the course of observation. The skin lesions in the D2 group were more severe than in the D0 group, but much milder than those in the untreated group. The D4 group exhibited almost the same course of skin lesions as that of the untreated group until day 6, then the skin lesions recovered gradually. In one of the three experiments in the D0 group, lesions began to redevelop between days 6 and 9, after which the mice recovered again.
DTH reaction to HSV antigen
The skin test representing the DTH reaction to HSV antigen was conducted on day 21 after infection or immunization, during a convalescent period. Each mouse was inoculated intradermally in the right footpad with UVinactivated virus equivalent to the dose used for infection. The reaction was evaluated on the basis of an increase in the footpad thickness at 24 h, 36 h and 48 h. (Figure 2a ) of the two groups, D0 and D2, with less progressed skin lesions was significantly enhanced compared to that of the D4 group in the cutaneous infection model. The swelling in the D0 group peaked at 24 h and in the D2 group at 36 h, with swelling of both groups decreasing slowly over time. However, the swelling in the D4 group peaked at 24 h and then decreased quickly. In mice immunized with inactivated HSV antigen, only a little swelling after DTH challenge was observed and no significant difference between groups was observed (Figure 2b) . Thus, immunization with inactivated HSV antigen failed to induce DTH in any acyclovir treatment groups, in contrast to treated groups after HSV infection (Figure 2a ).
Antibody response to cutaneous HSV infection and intradermal immunization
Convalescent sera from both the infected and immunized mice were analysed for the quantity of HSV-specific IgG and IgG isotype antibodies by ELISA. The results are Mice were divided into five groups as described in Methods. ACV, acyclovir. The IC (infected control) group showed the most severe skin lesions; 19 out of 20 mice died after 6 days. shown in Figure 3 . Infected mice in the D4 group (shorter acyclovir treatment; Figure 3a ) had significantly higher levels of IgG antibody than the two groups with less progressed skin lesions (D0 and D2). In the immunized mice, a similar level of IgG antibody production in all groups except UC was observed (Figure 3b ). Of the three IgG isotypes found in cutaneously infected mice, all groups showed dominance of the IgG2a isotype (Figure 4a) . However, the relative ratio of IgG2a:IgG1 was higher in the two longer acyclovir treatment groups (D0 and D2) than in the D4 group and the ratio in the D2 group was significantly higher than in the D4 group (Table 2 ). In immunized mice there was no significant difference in the level of the isotype antibody titre among groups (Figure 4b) . However, when the isostype antibody titre in immunization groups was compared to that in the infected D4 group, there was significantly lower IgG1 and higher IgG2a in the D4 group.
Discussion
This study was designed to analyse the effect of acyclovir treatment on the development of skin lesions and subsequently, the modulation of the immune response to HSV. Acyclovir treatment starting at days 0, 2 and 4 p.i. successfully modified the development of skin lesions.
The immune responses including DTH and antibody production of mice treated with acyclovir were compared in three separate experiments with similar results being obtained. We observed the redevelopment of skin lesions from day 6 to 9 in one of the three experiments, however the mice recovered quickly.
From our results, acyclovir treatment exerted no effects on antibody production in mice immunized with inactivated HSV antigen that failed to induce DTH. In the case of cutaneous infection, when the skin lesions were mainly within the epidermis (a score of 2 or 4), DTH to the HSV antigen was stronger than in those mice with a score of more than 4 in the three experiments. In contrast, antibody production was a reverse of the results with DTH. This indicated that the skin lesions modified by acyclovir determine the immune response rather than acyclovir treatment itself.
This discrepancy in the immune response to HSV antigen between DTH and antibody formation is referred to as immune deviation (Asherson & Stone, 1965; Parish, 1971; Katsura, 1977; Finkelman, 1995) . Using an injection of antigen-pulsed spleen dendritic cells into mice, Kuribayashi et al. (1997) found that there is an inverse relationship between ear DTH reaction after keyhole limpet haemocyanin antigen challenge and serum antibody titre. Langerhans cells in the epidermis play an important role in the induction of DTH response in HSV infection (Sprecher & Becker, 1987; Hendricks et al., 1992 (Mosmann & Coffman, 1989; Manickan et al., 1995; Rizzo et al., 1995; Abbas et al., 1996) . On the other hand, once Th2 cells are stimulated, Th2-type cytokines, such as IL-4 and IL-10, may progress, to both suppress the DTH reaction and enhance the production of antibody, especially IgG1. Thus, skin lesions being limited to the epidermis or being allowed to progress to the dermis by the different acyclovir treatment period, determined the development of Th1 or Th2 type response and caused the deviation of the immune response to the HSV antigen. Isotype antibody production in immunization groups is shown in Figure 4b and compared with cutaneous infection under ID4 treatment. It clearly shows that cutaneous infection significantly increased the ratio of IgG2a:IgG1 in comparison with immunization groups. The IgG isotype antibody production was modified by infection and ID4 showed lower IgG1 and higher IgG2a than immunization groups. This may be due to the strong stimulation of Langerhans cells by cutaneous infection, resulting in Th1-type IgG2a predominance. The ratio of IgG2a:IgG1 was associated with the magnitude of the DTH response in infected mice treated with acyclovir, as shown in Table 2 and it was lowest in the D4 group, although IgG2a was highest in the D4 group. This may be due to both the strong induction of DTH by cutaneous infection even in the D4 group, despite the use of BALB/c mice, which are Th2 response-dominant (Sadick et al., 1986; Scott et al., 1988; D'Orazio & Niederkorn, 1998) . The results of the relative amounts of IgG isotype antibody may be consistent with those of the neutralizing antibody to glycoprotein gD in HSV infection (Ishizaka et al., 1995) .
We also checked the lymphoproliferative response of spleen cells as described previously (Rand et al., 1976; Azmi & Field, 1993; Richards et al., 1998; Sato et al., 1998) . We observed a tendency of the mean [ 3 H]thymidine uptake and stimulation index to increase with the severity of skin lesions (data not shown). Mice with shorter acyclovir treatment (D4 group) showed more uptake of [ 3 H]thymidine and a bigger stimulation index than those with longer acyclovir treatment (D0 and D2 groups). This is consistent with clinical results in patients undergoing acyclovir treatment, as reported by Lafferty et al. (1984) and Mitchell et al. (1986) . Clinical observations concerning the immune response of HSV-infected patients showed a lower antibody titre in acyclovir-treated patients than in placebo-treated patients, resulting in suppression of antibody response or lymphoproliferative responses to HSV (Ashley & Corey, 1984; Bernstein et al., 1984; Lafferty et al., 1984; Mitchell et al., 1986; Erlich et al., 1988; Gold et al., 1988; Ragab et al., 1989; Kawana et al., 1995; Hu et al., 1997) . Results of the present study would be applicable in interpreting those observations, although it is difficult to deny the possibility that antibody titre is dependent on the severity of skin lesions. Low antibody response may not be due to true immunosuppression, but rather to immune deviation. It would be necessary to assess the antibody response as well as the DTH response in order to evaluate the effect of acyclovir treatment on the immune response in patients with acute HSV infection. Varicella-zoster virus (VZV) infection induces a strong DTH response to VZV antigen and the varicella skin test antigen has been developed for evaluating immunity to VZV (Kamiya et al., 1977; Asano et al., 1981; Shiraki et al., 1984) . Reactivity to the varicella skin test antigen correlates with the clinical course of zoster better than the antibody response (Hata, 1980; Takahashi et al., 1992) . DTH representing local immunity may be more important than antibody in VZV; however, it is difficult to assess DTH in HSV infection. Together with the observations, the present results indicate clinical observations of the suppression in antibody production by acyclovir treatment should possibly be considered to be caused by immune deviation and not immunosuppression.
